These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 18182677

  • 1. Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?
    De Maeyer L, Van Limbergen E, De Nys K, Moerman P, Pochet N, Hendrickx W, Wildiers H, Paridaens R, Smeets A, Christiaens MR, Vergote I, Leunen K, Amant F, Neven P.
    J Clin Oncol; 2008 Jan 10; 26(2):335-6; author reply 336-8. PubMed ID: 18182677
    [No Abstract] [Full Text] [Related]

  • 2. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
    Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, Nicholson RI, Lee AH, Robertson JF, Ellis IO.
    J Clin Oncol; 2007 Oct 20; 25(30):4772-8. PubMed ID: 17876012
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Clinicopathological characteristics and prognostic significance of young patients with triple-negative breast cancer].
    Zhang P, Xu BH, Ma F, Li Q.
    Zhonghua Zhong Liu Za Zhi; 2010 Feb 20; 32(2):128-31. PubMed ID: 20403244
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
    Webster LR, Lee SF, Ringland C, Morey AL, Hanby AM, Morgan G, Byth K, Mote PA, Provan PJ, Ellis IO, Green AR, Lamoury G, Ravdin P, Clarke CL, Ward RL, Balleine RL, Hawkins NJ.
    Clin Cancer Res; 2008 Oct 15; 14(20):6625-33. PubMed ID: 18927304
    [Abstract] [Full Text] [Related]

  • 10. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
    Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL, Harris JR.
    J Clin Oncol; 2008 May 10; 26(14):2373-8. PubMed ID: 18413639
    [Abstract] [Full Text] [Related]

  • 11. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
    Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D, Sasano H, Carder P, Cussac AL, Knox F, Speirs V, Forbes J, Buzdar A.
    J Clin Oncol; 2008 Mar 01; 26(7):1059-65. PubMed ID: 18227529
    [Abstract] [Full Text] [Related]

  • 12. Is triple negative a prognostic factor in breast cancer?
    Nishimura R, Arima N.
    Breast Cancer; 2008 Mar 01; 15(4):303-8. PubMed ID: 18369692
    [Abstract] [Full Text] [Related]

  • 13. Isolated loss of hormonal receptors in leptomeningeal metastasis from estrogen receptor- and progesterone receptor-positive lobular breast cancer.
    Grewal J, Zhou H, Factor R, Kesari S.
    J Clin Oncol; 2010 May 01; 28(13):e200-2. PubMed ID: 20124173
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
    Wei B, Wang J, Bourne P, Yang Q, Hicks D, Bu H, Tang P.
    Hum Pathol; 2008 Dec 01; 39(12):1809-15. PubMed ID: 18715613
    [Abstract] [Full Text] [Related]

  • 17. Disease related indicators for a proper choice of adjuvant treatments.
    Hayes DF.
    Breast; 2011 Oct 01; 20 Suppl 3():S162-4. PubMed ID: 22015287
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Menopausal hormone therapy and breast cancer phenotype: does dose matter?
    Garwood ER, Kumar AS, Shim V.
    Ann Surg Oncol; 2008 Sep 01; 15(9):2526-32. PubMed ID: 18618187
    [Abstract] [Full Text] [Related]

  • 20. Low activation of Insulin-like Growth Factor 1-Receptor (IGF1R) is associated with local recurrence in early breast carcinoma.
    Peiró G, Benlloch S, Sánchez-Tejada L, Adrover E, Lerma E, Peiró FM, Sánchez-Payá J, Aranda FI.
    Breast Cancer Res Treat; 2009 Sep 01; 117(2):433-41. PubMed ID: 18683043
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.